



Fax: 877-342-4596  
Phone: 855-856-0536

# Pulmonary Arterial Hypertension Enrollment Form



Please detach before submitting to a pharmacy - tear here.

## PATIENT INFORMATION

Please complete the following or send patient demographic sheet

Patient Name \_\_\_\_\_  
Address \_\_\_\_\_  
Address 2 \_\_\_\_\_  
City, State, ZIP \_\_\_\_\_  
Home Phone \_\_\_\_\_ Alternate Phone \_\_\_\_\_  
DOB \_\_\_\_\_ Last Four of SS# \_\_\_\_\_ Gender \_\_\_\_\_  
Language Preference:  English  Spanish  Other \_\_\_\_\_

## PRESCRIBER INFORMATION

Prescriber's Name \_\_\_\_\_  
DEA \_\_\_\_\_  
NPI \_\_\_\_\_  
Group/Hospital \_\_\_\_\_  
Address \_\_\_\_\_  
City, State, ZIP \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_  
Contact Person \_\_\_\_\_ Phone \_\_\_\_\_

## INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)

Prior Authorization Reference number \_\_\_\_\_

## MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)

**Diagnosis** — Please include diagnosis name with ICD-10 code

Primary Pulmonary arterial hypertension (PAH) — I27.0  
      Idiopathic                       Familial  
 Secondary Pulmonary arterial hypertension (PAH) — I27.21  
      Connective Tissue Disorder     HIV  
      CTEPH                                 Associated  
 Other specified pulmonary heart diseases — I27.89 \_\_\_\_\_  
 Other Diagnosis: ICD-10 Code \_\_\_\_\_  
     Description \_\_\_\_\_  
Date of Diagnosis \_\_\_\_\_  
NYHA Functional Classification:  I  II  III  IV  
Mean PAP \_\_\_\_\_ PAOP \_\_\_\_\_  
Acute Pulmonary Vasoreactivity \_\_\_\_\_  
**Start Date** \_\_\_\_\_ **Review Date** \_\_\_\_\_

**Additional Information**

Therapy:  New  Reauthorization  Restart

Weight \_\_\_\_\_ kg/lbs Height \_\_\_\_\_ cm/in  
Allergies \_\_\_\_\_  
Lab Data \_\_\_\_\_  
Prior Therapies \_\_\_\_\_  
 Oxygen Therapy \_\_\_\_\_  
Concomitant Medications \_\_\_\_\_  
Additional Comments \_\_\_\_\_

## PRESCRIPTION INFORMATION

Medication	Dose / Strength	Directions	Quantity	Refills
<input type="checkbox"/> Adcirca®	<input type="checkbox"/> 20 mg Tablet			
<input type="checkbox"/> Revatio®	<input type="checkbox"/> 20 mg Tablet <input type="checkbox"/> 10 mg/12.5 mL IV Solution <input type="checkbox"/> 10 mg/mL Powder for Oral Suspension			
<input type="checkbox"/> Letairis® Patient enrollment required in Ambrisentan REMS program. Please call 888-417-3172.	<input type="checkbox"/> 5 mg Tablet <input type="checkbox"/> 10 mg Tablet			
<input type="checkbox"/> Tracleer® Patient enrollment required in Bosentan REMS program. Please call 866-359-2612.	<input type="checkbox"/> 32 mg Tablet for Oral Suspension <input type="checkbox"/> 62.5 mg Tablet <input type="checkbox"/> 125 mg Tablet			

**\*Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to:  Patient  Office  Other \_\_\_\_\_ Date \_\_\_\_\_ Needs by Date \_\_\_\_\_  
 Product Substitution permitted  Dispense as Written

Prescriber's Signature \_\_\_\_\_ Date: \_\_\_\_\_ Supervising Physician Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
Electronic or digital signatures not accepted.

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.